92 related articles for article (PubMed ID: 14520367)
1. Tumors hijack fetal enzyme, escape killer T cells.
Schepers K; Schumacher TN
Nat Med; 2003 Oct; 9(10):1253-4. PubMed ID: 14520367
[No Abstract] [Full Text] [Related]
2. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.
Uyttenhove C; Pilotte L; Théate I; Stroobant V; Colau D; Parmentier N; Boon T; Van den Eynde BJ
Nat Med; 2003 Oct; 9(10):1269-74. PubMed ID: 14502282
[TBL] [Abstract][Full Text] [Related]
3. Immunology. Fetal fascination.
Heemels MT
Nature; 1998 Aug; 394(6696):831. PubMed ID: 9732864
[No Abstract] [Full Text] [Related]
4. Tumor immune escape mediated by indoleamine 2,3-dioxygenase.
Zamanakou M; Germenis AE; Karanikas V
Immunol Lett; 2007 Aug; 111(2):69-75. PubMed ID: 17644189
[TBL] [Abstract][Full Text] [Related]
5. Prevention of allogeneic fetal rejection by tryptophan catabolism.
Munn DH; Zhou M; Attwood JT; Bondarev I; Conway SJ; Marshall B; Brown C; Mellor AL
Science; 1998 Aug; 281(5380):1191-3. PubMed ID: 9712583
[TBL] [Abstract][Full Text] [Related]
6. [A new mechanism of tumor resistance to the immune system, based on tryptophan breakdown by indoleamine 2,3-dioxygenase].
Van den Eynde B
Bull Mem Acad R Med Belg; 2003; 158(7-9):356-63; discussion 364-5. PubMed ID: 15132006
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta.
Kudo Y; Boyd CA; Spyropoulou I; Redman CW; Takikawa O; Katsuki T; Hara T; Ohama K; Sargent IL
J Reprod Immunol; 2004 Apr; 61(2):87-98. PubMed ID: 15063632
[TBL] [Abstract][Full Text] [Related]
8. How embryos may avoid immune attack.
Gura T
Science; 1998 Aug; 281(5380):1122-4. PubMed ID: 9735025
[No Abstract] [Full Text] [Related]
9. [How does fetus cheat mother's T-cells?].
Kaaja R
Duodecim; 1999; 115(7):741-2. PubMed ID: 11859507
[No Abstract] [Full Text] [Related]
10. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts.
Miki T; Sun H; Lee Y; Tandin A; Kovscek AM; Subbotin V; Fung JJ; Valdivia LA
Transplant Proc; 2001; 33(1-2):129-30. PubMed ID: 11266740
[No Abstract] [Full Text] [Related]
11. Modulation of tryptophan catabolism by regulatory T cells.
Fallarino F; Grohmann U; Hwang KW; Orabona C; Vacca C; Bianchi R; Belladonna ML; Fioretti MC; Alegre ML; Puccetti P
Nat Immunol; 2003 Dec; 4(12):1206-12. PubMed ID: 14578884
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment and immune escape.
Ferrone S; Whiteside TL
Surg Oncol Clin N Am; 2007 Oct; 16(4):755-74, viii. PubMed ID: 18022543
[TBL] [Abstract][Full Text] [Related]
13. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
Wang E; Selleri S; Marincola FM
Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
[No Abstract] [Full Text] [Related]
14. Killer dendritic cells: IKDC and the others.
Bonmort M; Dalod M; Mignot G; Ullrich E; Chaput N; Zitvogel L
Curr Opin Immunol; 2008 Oct; 20(5):558-65. PubMed ID: 18554881
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.
Muller AJ; DuHadaway JB; Donover PS; Sutanto-Ward E; Prendergast GC
Nat Med; 2005 Mar; 11(3):312-9. PubMed ID: 15711557
[TBL] [Abstract][Full Text] [Related]
16. Tumor-mediated apoptosis of cancer-specific T lymphocytes--reversing the "kiss of death"?
Trapani JA
Cancer Cell; 2002 Sep; 2(3):169-71. PubMed ID: 12242147
[TBL] [Abstract][Full Text] [Related]
17. Mouse model for allogeneic immune reaction against fetus recapitulates human pre-eclampsia.
Nishizawa H; Hasegawa K; Suzuki M; Achiwa Y; Kato T; Saito K; Kurahashi H; Udagawa Y
J Obstet Gynaecol Res; 2008 Feb; 34(1):1-6. PubMed ID: 18226121
[TBL] [Abstract][Full Text] [Related]
18. The physiology of immune evasion during pregnancy; the critical role of placental tryptophan metabolism and transport.
Kudo Y; Boyd CA
Pflugers Arch; 2001 Aug; 442(5):639-41. PubMed ID: 11512018
[No Abstract] [Full Text] [Related]
19. Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
Gajewski TF
Curr Opin Investig Drugs; 2004 Dec; 5(12):1279-83. PubMed ID: 15648949
[TBL] [Abstract][Full Text] [Related]
20. IDO: a crossroads of immunology and physiology?
Entrican G
J Reprod Immunol; 2004 Apr; 61(2):63-5. PubMed ID: 15063629
[No Abstract] [Full Text] [Related]
[Next] [New Search]
